{"title":"10 years in lupus - progress, but not enough.","authors":"Eric F Morand, Sarah A Jones","doi":"10.1016/j.molmed.2025.06.003","DOIUrl":"https://doi.org/10.1016/j.molmed.2025.06.003","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE, lupus) remains an enigmatic diagnosis with a poor prognosis. SLE is characterised by complex biology and heterogeneous clinical manifestations that create a major hurdle to the approval of new medicines and contribute to multiple trial failures. While the pace of research has accelerated, drugs currently in development target a limited spectrum of mechanisms, tempering hope that any will be a panacea. The pace of translation lags behind advances in basic science, and this continues to cost patients dearly. The unacceptable metabolic adverse effects of glucocorticoids have rightly driven treatment guidelines towards ever more stringent dose-reduction targets, and new research is ongoing to develop a safe and reliable glucocorticoid replacement that will be active across a breadth of inflammatory pathways.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guilherme H S Bomfim, Geneviève Dupont, Timothy Wright, Alan Mighell, Rodrigo S Lacruz
{"title":"Burden of hereditary enamel disorders.","authors":"Guilherme H S Bomfim, Geneviève Dupont, Timothy Wright, Alan Mighell, Rodrigo S Lacruz","doi":"10.1016/j.molmed.2025.06.002","DOIUrl":"10.1016/j.molmed.2025.06.002","url":null,"abstract":"<p><p>Dental enamel protects against the invasion of bacterial pathogens deep into the innervated layers of the tooth. Hereditary enamel disorders referred to as amelogenesis imperfecta (AI) can severely affect the development and mineralization of dental enamel compromising these functions. This rare disorder is often visible, carries a significant psychological and financial burden, and cosegregates with disease in other organs. Pathological variants in over 100 genes affect the enamel formation. Here, we describe the biology of enamel formation focusing on pathogenic variants underlying AI. We provide a computational model encapsulating new advances in calcium regulation during enamel formation. We also describe the psychological and financial burden of AI, its impact in systemic health, and discuss recent developments in diagnostic panels to detect AI.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New therapeutic approaches for fibrosis: harnessing translational regulation.","authors":"Sumeen Kaur Gill, Richard H Gomer","doi":"10.1016/j.molmed.2024.11.012","DOIUrl":"10.1016/j.molmed.2024.11.012","url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease characterized by excessive extracellular matrix deposition and tissue scarring. The median survival of patients with IPF is only 4.5 years following diagnosis, and effective treatment options are scarce. Recent studies found aberrant translation of specific mRNAs in various fibrosing diseases, highlighting the role of key translational regulators, including RNA binding proteins (RBPs), microRNAs, long noncoding RNAs, and transcript modifications. Notably, when inhibited, 10 profibrotic RBPs cause a significant attenuation of fibrosis, illuminating potential therapeutic targets. In this review, we describe translational regulation in fibrosis and highlight a model where a conserved evolutionary mechanism may explain this regulation.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"640-651"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nanocarrier vaccines for respiratory infections.","authors":"Yinghan Jiang, Luping Lei, Mengyuan Zhao, Yuxin Tian, Yuanyu Huang, Minghui Yang","doi":"10.1016/j.molmed.2024.12.002","DOIUrl":"10.1016/j.molmed.2024.12.002","url":null,"abstract":"<p><p>Respiratory infections continue to pose a major global health challenge, leading to high morbidity and mortality. Effective vaccines are crucial for prevention of these, and nanotechnology offers a promising approach to enhance vaccine efficacy through nanocarrier systems. This review explores recent advances in nanocarrier-based vaccines for respiratory pathogens, focusing on their ability to promote mucosal immunity against viral infections. It examines various types of nanocarriers, their physicochemical properties, and their role in improving vaccine delivery and immune responses. Additionally, the review examines key findings from both preclinical and clinical studies, highlighting the progress and challenges in developing nanocarrier vaccines for respiratory infections. These insights underscore the potential of nanotechnology to transform vaccine strategies and address unmet needs in respiratory disease prevention.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"652-668"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gut microbiota and bilirubin metabolism: unveiling new pathways in health and disease.","authors":"Libor Vítek, Claudio Tiribelli","doi":"10.1016/j.molmed.2024.12.007","DOIUrl":"10.1016/j.molmed.2024.12.007","url":null,"abstract":"<p><p>Bilirubin reductase (BilR), a gut microbiota-derived enzyme that reduces bilirubin to urobilinogen, was recently identified. Given the role of bilirubin in preventing modern diseases, understanding the link between the gut microbiota and health via modulation of bilirubin metabolism marks a major advance in medical research and potential treatments.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"591-594"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Iannis E Adamopoulos, Xenofon Baraliakos, Christopher Ritchlin
{"title":"Psoriatic arthritis: diagnosis, pathogenesis, and emerging therapies.","authors":"Iannis E Adamopoulos, Xenofon Baraliakos, Christopher Ritchlin","doi":"10.1016/j.molmed.2025.05.003","DOIUrl":"10.1016/j.molmed.2025.05.003","url":null,"abstract":"","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"682-683"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Splicing dysregulation: hallmark and therapeutic opportunity in pancreatic cancer.","authors":"Chiara Naro, Veronica Ruta, Claudio Sette","doi":"10.1016/j.molmed.2024.11.007","DOIUrl":"10.1016/j.molmed.2024.11.007","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by dismal prognosis. Late diagnosis, resistance to chemotherapy, and lack of efficacious targeted therapies render PDAC almost untreatable. Dysregulation of splicing, the process that excises the introns from nascent transcripts, is emerging as a hallmark of PDAC and a possible vulnerability of this devastating cancer. Splicing factors are deregulated in PDAC and contribute to all steps of tumorigenesis, from inflammation-related early events to metastasis and acquisition of chemoresistance. At the same time, splicing dysregulation offers a therapeutic opportunity to target cancer-specific vulnerabilities. We discuss mounting evidence that splicing plays a key role in PDAC and the opportunities that this essential process offers for developing new targeted therapies.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"610-624"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142795168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rahil Alhumaidi, Huihui Huang, Marie Christelle Saade, Amanda J Clark, Samir M Parikh
{"title":"NAD<sup>+</sup> metabolism in acute kidney injury and chronic kidney disease transition.","authors":"Rahil Alhumaidi, Huihui Huang, Marie Christelle Saade, Amanda J Clark, Samir M Parikh","doi":"10.1016/j.molmed.2024.12.004","DOIUrl":"10.1016/j.molmed.2024.12.004","url":null,"abstract":"<p><p>Disturbances in kidney tubular cell metabolism are increasingly recognized as a feature of acute kidney injury (AKI). In AKI, tubular epithelial cells undergo abnormal metabolic shifts that notably disrupt NAD<sup>+</sup> metabolism. Recent advancements have highlighted the critical role of NAD<sup>+</sup> metabolism in AKI, revealing that acute disruptions may lead to lasting cellular changes, thereby promoting the transition to chronic kidney disease (CKD). This review explores the molecular mechanisms underlying metabolic dysfunction in AKI, with a focus on NAD<sup>+</sup> metabolism, and proposes several cellular processes through which acute aberrations in NAD<sup>+</sup> may contribute to long-term changes in the kidney.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"669-681"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"IL-6: a pivotal molecule for tumor-brain dysfunction interaction.","authors":"Yuan-Yuan Wang, Yong-Fei Wang, Wei-Lin Jin","doi":"10.1016/j.molmed.2025.05.004","DOIUrl":"10.1016/j.molmed.2025.05.004","url":null,"abstract":"<p><p>Neuropsychiatric complications of cancer cachexia include apathy. Zhu et al. identified a brain circuit sensitive to tumor-driven interleukin-6 (IL-6) signaling that directly reduces motivation by suppressing dopaminergic activity. Targeted circuit-based and pharmacologic interventions, including systemic anti-IL-6 antibodies, reversed motivational deficits and point to new therapeutic avenues for apathy.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"585-587"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Short-chain fatty acids in fetal development and metabolism.","authors":"Xueyun Qin, Mo Zhang, Shiting Chen, Yunhui Tang, Jiajun Cui, Guolian Ding","doi":"10.1016/j.molmed.2024.11.014","DOIUrl":"10.1016/j.molmed.2024.11.014","url":null,"abstract":"<p><p>Short-chain fatty acids (SCFAs), primarily derived from gut microbiota, play a role in regulating fetal development; however, the mechanism remains unclear. Fetal SCFAs levels depends on maternal SCFAs transported via the placenta. Metabolic stress, particularly from diabetes and obesity, can disrupt maternal SCFAs levels, impairing fetal metabolic reprogramming. Dysregulated SCFAs may negatively impact the development of the fetal cardiovascular, nervous, and immune systems, potentially contributing to adverse outcomes in adulthood. This review focuses on recent advances regarding the role of maternal SCFAs in shaping the metabolic profile of offspring, especially in the context of various maternal metabolic disorders. Given that SCFAs may influence fetal development through the placenta-embryo axis, targeted SCFAs supplementation could be a promising strategy against developmental diseases associated with intrauterine risk factors.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"625-639"},"PeriodicalIF":12.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}